Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by brad129on Feb 01, 2022 8:43pm
206 Views
Post# 34387613

RE:RE:Care

RE:RE:Care

great reply, these are only the consultations appointments, I'm sure the staff is still on a payroll next week, open them up get them booked and have people remember they had to wait just for the consultation so they better pony up and buy the test, after all it's in high demand.




davewho wrote: maybe they were unprepared for the avalanche of new patients and just aren't setup at the moment for any more than weekly bookings. The rate of available time slots filling is pretty impressive. If they want to increase it that could change any day as the demand keeps rising. Monthly bookings would be nice to see. That would be a great indicator of how things are going with Avrt and Aristotle. Could also be a competition issue. They don't want others knowing just what they are doing and how much they are doing. A hostile take over out at this level would not be good for the company or shareholders. Also setting a low number of appointments available is actually a common sales practice. It builds more demand at higher prices. Take your pick. All of the above or maybe there are other reasons. We just don't know until the next Q and CC.

 

<< Previous
Bullboard Posts
Next >>